US 11174316
Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
granted A61KA61K2039/505A61K39/3955
Quick answer
US patent 11174316 (Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof) held by CytomX Therapeutics, Inc. expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- CytomX Therapeutics, Inc.
- Grant date
- Tue Nov 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 19
- CPC classes
- A61K, A61K2039/505, A61K39/3955, A61K49/0021, A61K49/0041